Compare CTMX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | BNR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.9M | 126.5M |
| IPO Year | 2015 | 2019 |
| Metric | CTMX | BNR |
|---|---|---|
| Price | $2.82 | $11.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.10 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 46.8K |
| Earning Date | 05-08-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $76,201,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $6.79 |
| 52 Week High | $8.21 | $41.72 |
| Indicator | CTMX | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 29.17 | 57.68 |
| Support Level | N/A | $8.91 |
| Resistance Level | $3.93 | $12.89 |
| Average True Range (ATR) | 0.22 | 1.12 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 2.05 | 61.56 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.